NEUmiRNA is developing innovative first-in-class therapies targeting microRNAs in the central nervous system. Its lead candidate, focused on drug-resistant epilepsy, has shown potential to reverse disease progression in preclinical models.
- CEO: Ellen Donnelly, PhD
- Advisor and co-founder: Henrik Klitgaard
- Location: Dinamarca
- Web: neumirna.com